Azo-Standard
(Phenazopyridine)ApprovedSmall molecule
This medication relieves pain, burning, and discomfort in the urinary tract and reduces urgent and frequent urination caused by infections, surgery, or medical procedures. However, it does not treat or cure infections.[2] Azo-Standard is currently approved and in use across 2 indications[4].[1]
Azo-Standard is one of 27 small molecule programs targeting Dysuria. It is currently in Approved.
2
Indications
11
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
37 competitors in Urinary Retention
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Robinul
Alnylam PharmaceuticalsApproved
Avodart
Akero TherapeuticsApproved
Ivadantin
PProcter and Gamble
Approved
Esmeron
FFresenius Kabi Oncology Ltd.
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Uroxatral
AAdvanz Pharma
Phase 3
Tamsulosin OCAS
AstellasPhase 3
Zanaflex
LLegacy Health System
Phase 3
Azo-Standard
UUniversity of Massachusetts, Worcester
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Analgesia2 trials
Dysuria1 trial
Oral1 trial
2 more indications
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Azo-Standard drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Phenazopyridine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details